Jun Qi

26.3k total citations · 4 hit papers
177 papers, 9.3k citations indexed

About

Jun Qi is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jun Qi has authored 177 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Molecular Biology, 47 papers in Hematology and 31 papers in Oncology. Recurrent topics in Jun Qi's work include Protein Degradation and Inhibitors (86 papers), Multiple Myeloma Research and Treatments (36 papers) and Ubiquitin and proteasome pathways (35 papers). Jun Qi is often cited by papers focused on Protein Degradation and Inhibitors (86 papers), Multiple Myeloma Research and Treatments (36 papers) and Ubiquitin and proteasome pathways (35 papers). Jun Qi collaborates with scholars based in United States, China and United Kingdom. Jun Qi's co-authors include James E. Bradner, Andrew L. Kung, Junwei Shi, Christopher R. Vakoc, Scott J. Rodig, Scott W. Lowe, Meredith J. Taylor, Mark Wunderlich, James C. Mulloy and Peter Valent and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jun Qi

166 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

2011 1.4k citations Jun Qi, James E. Bradner et al. profile →
The dTAG system for immediate and target-specific protein degradation

2018 652 citations Joshiawa Paulk, Matthew A. Lawlor et al. profile →
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

2013 550 citations Charles Y. Lin, Jun Qi et al. profile →
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jun Qi	7.7k	2.3k	1.8k	698	611	177	9.3k
Kathleen M. Sakamoto	6.2k 0.8×	1.3k 0.6×	2.3k 1.3×	699 1.0×	983 1.6×	188	8.2k
Sharon Shacham	4.4k 0.6×	1.3k 0.6×	1.4k 0.8×	369 0.5×	327 0.5×	221	5.8k
Paolo Salomoni	4.8k 0.6×	1.1k 0.5×	1.4k 0.8×	776 1.1×	852 1.4×	104	6.5k
Silvano Capitani	4.8k 0.6×	975 0.4×	1.3k 0.7×	711 1.0×	1.6k 2.6×	262	7.9k
Anke Klippel	6.2k 0.8×	544 0.2×	1.3k 0.7×	831 1.2×	967 1.6×	67	8.0k
Anskar Y.H. Leung	2.9k 0.4×	712 0.3×	1.3k 0.7×	493 0.7×	1.1k 1.8×	112	5.5k
Antonia Follenzi	4.6k 0.6×	801 0.4×	1.0k 0.6×	614 0.9×	945 1.5×	156	8.9k
Shinichi Saito	6.1k 0.8×	589 0.3×	4.0k 2.2×	1.2k 1.8×	694 1.1×	115	9.4k
Frank N. van Leeuwen	3.3k 0.4×	850 0.4×	593 0.3×	480 0.7×	792 1.3×	112	6.7k
Clara Nervi	8.1k 1.1×	3.1k 1.4×	681 0.4×	1.7k 2.4×	775 1.3×	121	9.2k

Countries citing papers authored by Jun Qi

Since Specialization

Citations

This map shows the geographic impact of Jun Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Qi more than expected).

Fields of papers citing papers by Jun Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Qi. The network helps show where Jun Qi may publish in the future.

Co-authorship network of co-authors of Jun Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Qi. A scholar is included among the top collaborators of Jun Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Qi. Jun Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Kaihua, Bin Hu, Yi Jiang, et al.. (2025). Comprehensive insights into the mechanism of flavor formation in mandarin fish (Siniperca chuatsi) with inoculated fermentation. Food Chemistry. 479. 143717–143717. 1 indexed citations

Laurent, Jessica D. St., Ajinkya Patil, João A. Paulo, et al.. (2025). Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas. Nature Genetics. 57(11). 2743–2755. 1 indexed citations

Spisák, Sándor, David J. Chen, Zhixin Li, et al.. (2024). Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system. Nature Communications. 15(1). 2230–2230. 5 indexed citations

Hassan, Muhammad Murtaza, Yen-Der Li, W Michelle, et al.. (2024). Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. European Journal of Medicinal Chemistry. 279. 116904–116904. 12 indexed citations

Berndt, Norbert, et al.. (2022). Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. Journal of Medicinal Chemistry. 65(15). 10441–10458. 12 indexed citations

Zhou, Dawei, Tsuyoshi Hayashi, Weili Kong, et al.. (2020). Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 ⁺ T cells ex vivo. Science Advances. 6(29). eaba1941–eaba1941. 14 indexed citations

Stratton, Matthew S., Rushita A. Bagchi, Marina Barreto Felisbino, et al.. (2019). Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circulation Research. 125(7). 662–677. 123 indexed citations

Ye, Shuai, Matthew A. Lawlor, Shaun Egolf, et al.. (2018). YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis. Cancer Research. 78(10). 2705–2720. 45 indexed citations

Chakraborty, Abhishek A., Eijiro Nakamura, Jun Qi, et al.. (2017). HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine. 9(398). 36 indexed citations

10.

Xie, Huafeng, Cong Peng, Jialiang Huang, et al.. (2016). Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discovery. 6(11). 1237–1247. 73 indexed citations

11.

Mishra, Anjali, Krista La Perle, Laura A. Sullivan, et al.. (2016). Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discovery. 6(9). 986–1005. 75 indexed citations

12.

Zhu, Xuguang, Keisuke Enomoto, Li Zhao, et al.. (2016). Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clinical Cancer Research. 23(2). 430–440. 44 indexed citations

13.

Stubbs, Matthew C., Won-Il Kim, Tina Davis, et al.. (2015). Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 21(10). 2348–2358. 59 indexed citations

14.

Liu, Suhu, Sarah R. Walker, Erik A. Nelson, et al.. (2014). Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2. Molecular Cancer Therapeutics. 13(5). 1194–1205. 51 indexed citations

15.

Cho, Hyejin, Tali Herzka, Zheng Wu, et al.. (2014). RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten -Mutant Metastasis. Cancer Discovery. 4(3). 318–333. 68 indexed citations

16.

Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Molecular Cancer Therapeutics. 13(5). 1142–1154. 155 indexed citations

17.

Fiskus, Warren, Sunil Sharma, Jun Qi, et al.. (2014). BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. Molecular Cancer Therapeutics. 13(10). 2315–2327. 112 indexed citations

18.

Chan, Carmel T., Jun Qi, William Smith, et al.. (2014). Syntheses and Discovery of a Novel Class of Cinnamic Hydroxamates as Histone Deacetylase Inhibitors by Multimodality Molecular Imaging in Living Subjects. Cancer Research. 74(24). 7475–7486. 12 indexed citations

19.

Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →

20.

Shimamura, Takeshi, Zhao Chen, Margaret Soucheray, et al.. (2013). Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(22). 6183–6192. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact